Cinacalcet and achievement of the NKF/K-DOQITM recommended target values for bone and mineral metabolism in real-world clinical practice--the ECHO observational study

Abstract

This analysis of current European clinical practice shows that-consistent with findings from randomized controlled trials and retrospective observational studies-cinacalcet improves attainment of KDOQI bone metabolism targets in dialysis patients with various stages of SHPT.

Efficacy of Cinacalcet for the Treatment of Secondary Hyperparathyroidism in CKD Patients on Peritoneal or Hemo Dialysis: The Middle-East Experience

“…A similar response was observed in patients who were treated with PD and HD; 65% of patients in both groups experienced ≥30% reductions in iPTH levels with cinacalcet therapy. Similar efficacy in PD patients was demonstrated by Urena et al [21].…”

“…There have been numerous studies which have shown reduction of serum intact PTH with cinacalcet in patients on hemodialysis [19][20][21][22][23]. In the first large randomised controlled study (RCT) with 741 patients on maintenance dialysis and secondary HPT, Geofry et al in 2004 concluded that cinacalcet significantly reduces iPTH in patients with CKD-5D versus control [19].…”

“…Safety and efficacy of the calcimimetic cinacalcet has been evaluated in many randomized, and controlled trials which showed that the cinacalcet significantly reduces iPTH in patients with CKD on dialysis (CKD-5D) versus control [19,20].Among these studies only few have studied the efficacy of cinacalcet in PD patients with secondary HPT including those by Lindberg et al [20] and Urena et al [21] who showed that Cinacalcet had comparable efficacy in HD and PD patients; 50% of PD patients achieved a mean iPTH ≤300 those studies.…”

Clinical and Practical Use of Calcimimetics in Dialysis Patients With Secondary Hyperparathyroidism

“…The combined results of RCTs and phase 4 studies confirmed these results (11,13,21,(44)(45)(46)(47)(48)(49)(50)(51)(52)(53)(54)(55)(56)(57)(58)) (Table1), among other benefits, including a substantial reduction of the elevated bone formation rate/tissue area, generally improving bone disease (57,58). Importantly, two recent prospective RCTs evaluated both the efficacy of cinacalcet in preventing the progression of CV calcifications (ADVANCE) (11), and its effect on clinical outcomes, including all-cause mortality and CV events (EVOLVE) (13).…”

Cinacalcet in peritoneal dialysis patients: one-center experience

“…5,6 Until 2008, most of the published studies of cinacalcet in dialysis patients, included a small number of peritoneal dialysis (PD) patients. 7,8 A Spanish one-center observational prospective study of 18 patients under PD published in 2008, proved that the use of cinacalcet in PD patients with SHPT resistant to conventional treatment has resulted effective and safe and has improved compliance objectives of the guidelines. 9 This results were corroborated in 2012, in a Spanish multicenter observational prospective study of 54 PD patients.…”